The facility located in Ware, UK, will be used to manufacture GSK’s Ellipta inhaler.
GlaxoSmithKline (GSK) opened a £56 million (approximately $80.67 million) manufacturing facility in Ware, United Kingdom, according to an April 18, 2016 press announcement. The 4200-m2 facility will create 150 new jobs in the UK.
The Ware facility is the latest expansion of GSK’s Ellipta inhaler manufacturing. The company says they expect the opening of the facility to nearly double production of Ellipta inhalers to at least 37 million per year by 2017, 95% of which, the company said, will be exported.
Since 2013, over 400 roles will have been created at the manufacturing site in Ware, bringing the staff total to 1200, GSK said. This includes over 30 apprentice and 50 graduate roles.
Source: GlaxoSmithKline
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.